Fundraising Fox
/Companies
Sign in

Revitope Oncology

San Francisco, US · Founded 2016 · Delaware corporation

Find your way into Revitope Oncology

Sign up to see every warm intro you have to Revitope Oncology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Revitope Oncology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Revitope Oncology is a biotechnology company developing precision cancer immunotherapies using its TwoGATE T cell engager platform, which uses paired tumor-targeted bispecific antibodies that become active only on cancer cells co-expressing two antigens to limit toxicity to healthy tissue. Its pipeline focuses on solid tumor indications, developed in-house and through partnerships with companies such as Genmab and Junshi Biosciences.

BiotechDeep TechHealthtech

Founders & leadership

Revitope Oncology was founded in 2016 by Andrew Allen.

AAAndrew Allen
Andrew AllenChairman & Founder
JCJulie Cherrington
Julie CherringtonExecutive
SA
Steve ArkinstallChief Executive Officer
WM
Werner MeierChief Scientific Officer
MCMark Clement
Mark ClementChief Operating Officer
MC
Mark CobboldNamed on SEC filing

Board

RM
Raj MehtaBoard director
PJ
Peter JoostBoard director

Reported raises · per SEC filings

Form D private placements

$8.2M disclosed across 1 round · 2016

▶$8.2MraisedSep 2016 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark CobboldDirector
  • Julie CherringtonExecutive Officer, Director
  • Raj MehtaDirector
  • Peter JoostDirector
  • Andrew AllenExecutive Officer, Director
Offering amount
$8.2M
Amount sold
$8.2M
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Kyverna TherapeuticsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.

Companies working in the same space as Revitope Oncology.

In the news

Revitope Oncology, Inc. Raises $8.5 Million to Continue Development of Novel Cancer Immunotherapy Platformprnewswire.com · Feb 2016

Frequently asked questions

What does Revitope Oncology do?
Revitope Oncology is a biotechnology company developing precision cancer immunotherapies using its TwoGATE T cell engager platform, which uses paired tumor-targeted bispecific antibodies that become active only on cancer cells co-expressing two antigens to limit toxicity to healthy tissue. Its pipeline focuses on solid tumor indications, developed in-house and through partnerships with companies such as Genmab and Junshi Biosciences.
Who founded Revitope Oncology?
Revitope Oncology was founded by Andrew Allen in 2016.
How much funding has Revitope Oncology raised?
Revitope Oncology has disclosed $8.2M raised across 1 round.
Where is Revitope Oncology headquartered?
Revitope Oncology is headquartered in San Francisco, US.